Summary & Overview
HCPCS A9503: Technetium Tc-99m Medronate, Diagnostic, Up to 30 mCi
HCPCS Level II code A9503 denotes Technetium tc-99m medronate, a diagnostic radiopharmaceutical supplied per study dose up to 30 millicuries, commonly used for nuclear medicine bone imaging. The code identifies the agent administered during scintigraphic evaluation of skeletal pathology and is relevant to facility and professional billing for imaging services nationwide. Its designation matters for accurate reporting of radiopharmaceuticals, inventory management, and distinguishing drug supply from procedural and imaging charges.
Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, coding implications for radiopharmaceutical billing, common modifiers and their relevance to service lines, and clinical context for use in bone scintigraphy. The publication summarizes benchmarks where available, discusses coding and billing considerations for imaging facilities and nuclear medicine departments, and outlines scenarios affecting claim adjudication such as dose limits and supply reporting. Data not available in the input is noted where applicable. This summary is intended to support revenue cycle, compliance, and clinical teams in understanding the role of A9503 in diagnostic nuclear medicine workflows.
Billing Code Overview
HCPCS Level II code A9503 represents Technetium tc-99m medronate, a diagnostic radiopharmaceutical dosed per study dose, up to 30 millicuries. This product is used in nuclear medicine imaging procedures to evaluate bone metabolism and detect skeletal abnormalities.
Service type: Diagnostic radiopharmaceutical administration for nuclear medicine bone imaging
Typical site of service: Hospital outpatient imaging departments, freestanding imaging centers, and nuclear medicine suites
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred from primary care or orthopedics with persistent, unexplained localized bone pain, suspected occult fracture, or evaluation for metastatic bone disease. The patient arrives at an outpatient nuclear medicine or radiology department. After verification of identity, indications, and pregnancy status, a technologist and nuclear medicine physician review contraindications and obtain informed consent for a diagnostic nuclear medicine bone scan using technetium tc-99m medronate. The study dose, up to 30 millicuries, is administered intravenously as A9503. The patient returns for imaging at standard time intervals (typically 2–3 hours post-injection for planar and SPECT imaging). The nuclear medicine technologist performs whole-body planar images and targeted SPECT/CT as ordered. The interpreting physician documents findings, procedure details, administered activity in millicuries, and any adverse reactions. Billing uses A9503 for the radiopharmaceutical dose; imaging and interpretation are billed separately with applicable CPT codes and appropriate modifiers for professional or technical components as required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician interpretation component of the imaging study separate from the technical component. |